業績/英文


2012
1. Yamashita A, Nishihara K, Matsuura Y, Ito T, Kawahara K, Hatakeyama K, Hashiguchi T, Maruyama I, Yagi H, Matsumoto M, Fujimura Y, Kitamura K, Shibata Y, Asada Y. Paucity of CD34-positive cells and increased expression of high-mobility group box 1 in coronary thrombus with type 2 diabetes mellitus. Atherosclerosis 224 : 511-514, 2012.
2. Tanabe S, Yagi H, Kimura T, Isonishi A, Kato S, Yoshida Y, Hayakawa M, Matsumoto M, Ohtaki S, Takahashi Y, Fujimura Y. Two newborn-onset patients of Upshaw-Schulman syndrome with distinct subsequent clinical courses. Int J Hematol 96 : 789-797, 2012.
3. Yagi H, Yamaguchi N, Shida Y, Hayakawa M, Matsumoto M, Sugimoto M, Wada H, Tsubaki K, Fujimura Y. Cilostazol down-regulates the height of mural platelet thrombi formed under a high shear-rate flow in the absence of ADAMTS13. Eur J Pharmacol 15 : 151-155, 2012.
4. Igari A, Nakagawa T, Moriki T, Yamaguchi Y, Matsumoto M, Fujimura Y, Soejima K, Murata M. Identification of epitopes on ADAMTS13 recognized by a panel of monoclonal antibodies with functional or non-functional effects on catalytic activity. Thromb Res 130 : e79-83, 2012.
5. Morishima T, Nomura A, Saida S, Watanabe K, Yagi H, Matsumoto M, Fujimura Y, Heike T, Nakahata T, Adachi S. Pediatric idiopathic TTP diagnosed with decreased ADAMTS13 activity Pediatr Int 54 : 422-423, 2012.
6. Yamamoto-Suzuki Y, Sakurai Y, Fujimura Y, Matsumoto M, Hamako J, Kokubo T, Kitagawa H, Kawsar SM, Fujii Y, Ozeki Y, Matsushita F, Matsui T. Identification and recombinant analysis of botrocetin-2, a snake venom cofactor for von Willebrand factor-induced platelet agglutination. Biochemistry USA 51 : 5329-5338, 2012.
7. Taguchi F, Yagi H, Matsumoto M, Sadamura S, Isonishi A, Soejima K, Fujimura Y. The homozygous p.C1024R-ADAMTS13 gene mutation links to a late-onset phenotype of Upshaw-Schulman syndrome in Japan. Thromb Haemost 107 : 1003-1005, 2012.
8. Koyama N, Matsumoto M, Tamaki S, Yoshikawa M, Fujimura Y, Kimura H. Reduced larger von Willebrand factor multimers at dawn in OSA plasmas reflect severity of apnetic episodes. Eur Respir J 40 : 657-664, 2012.
9. Matsumoto M, Bennett CL, Qureshi Z, Isonishi A, Hori Y, Hayakawa M, Yoshida Y,Yagi H, Fujimura Y. Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan. PLoS ONE 7 e33029, 2012.
10. Yamamoto T, Fujimura Y, Emoto Y, Kuriu Y, Iino M, Matoba R. Autopsy case of sudden maternal death from thrombotic thrombocytopenic purpura. J Obstet Gynaecol Res 39 : 351-354, 2012.
11. Takaya H, Uemura M, Fujimura Y, Matsumoto M, Matsuyama T, Kato S, Morioka C, Ishizashi H, Hori Y, Fujimoto M, Tsujimoto T, Kawaratani H, Kurumatani N, Fukui H. The ADAMTS13 activity predicts the cumulative survival of patients with liver cirrhosis-in comparison with the Child-Turcotte-Pugh score and the MELD score. Hepatology Res 42 : 459-472, 2012.
12. Jacob S, Dunn BL, Qureshi ZP, Bandarenko N, Kwaan HC, Pandey DK, McKoy JM,Barnato SE, Winters JL, Cursio JF, Weiss I, Raife TJ, Carey PM, Sarode R, Kiss JE, Danielson C, Ortel TL, Clark WF, Rock G, Matsumoto M, Fujimura Y, Zheng XL, Chen H, Chen F, Armstrong JM, Raisch DW, Bennett CL. Ticlopidine-, Clopidogrel-, and Prasugrel- Associated Thrombotic Thrombocytopenic Purpura: A Twenty-Year Review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost 38 : 845-853, 2012.
13. Yagi H, Matsumoto M, Fujimura Y. Paradigm shift of childhood TTP with severe ADAMTS13 deficiency. Presse Medicale 41 : e137-155, 2012.

2011
1. Fujimura Y, Matsumoto M, Isonishi A, Yagi H, Kokame K, Soejima K, Murata M, Miyata T. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost(State of the art 2011) 9 : 283-301, 2011.
2. Akiyama R, Komori I, Hiramoto R, Isonishi A, Matsumoto M, Fujimura Y. H1N1 influenza (swine flu)-associated thrombotic microangiopathy with a remarkably high plasma ratio of von Wilebrand factor to ADAMTS13. Intern Med 50 : 643-647, 2011.
3. Yamaguchi Y, Moriki T, Igari A, Nakagawa T, Wada H, Matsumoto M, Fujimura Y, Murata M. Epitope analysis of autoantibodies to ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Thromb Res 128 : 169-173, 2011.
4. Uemura M, Fujimura Y, Ko S, Matsumoto M, Nakajima Y, Fukui H. Determination of ADAMTS13 and its clinical significance for ADAMTS13 supplementation therapy to improve the survival of patients with decompensated liver cirrhosis. Int J Hepatol e759047, 2011.

2010
1. Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: Database of Nara Medical University during 1998-2008. Intern Medicine 49: 7-15, 2010.
2. Uemura M, Fujimura Y, Ko S, Matsumoto M, Nakajima Y, Fukui H. Pivotal role of ADAMTS13 function in liver diseases. Int J Hematol (Review) 91:20-29, 2010.
3. Kosugi N, Tsurutani Y, Isonishi A, Hori Y, Matsumoto M, Fujimura Y. Influenza A infection triggers thrombotic thrombocytopenic purpura by producing the anti-ADAMTS13 IgG inhibitor. Intern Medicine (in press), 2010.
4. Okano E, Saiho K, Matsumoto M, Fujimura Y, Nakajima Y. ADAMTS13 activity decreases after hepatectomy, reflecting a postoperative liver function. Hepato-gastroenterology (in press), 2010.
5. Sato A, Hoshi Y, Onuma M, Sato R, Tsunematsu Y, Isonishi A, Matsumoto M, Fujimura Y, Imaizumi M. A 9-month-old infant with acquired idiopathic thrombotic thrombocytopenic purpura caused by inhibitory IgG-autoantibody to ADAMTS13. Pediatric Hematology-Oncology (in press), 2010.
6. Kato K, Kobayashi C, Katayama Y, Moriyama N, Shiono J, Kudo K, Koide K, Aoki K, Fujisawa K, Okada M, Matsumoto M, Fujimura Y, Tsuchida M. A 42-day-old boy with acute idiopathic thrombocytopenic purpura. Pediatr Int (in press), 2010.


2009
1. Ito N, Wada H, Matsumoto M, Fujimura Y, Murata M, Izuno T, Sugita M, Ikeda Y. National questionnaire survey of TMA. Int J Hematol 90: 328-335, 2009.
2. Watanabe N, Ikeda H, Kume Y, Satoh Y, Takai D, Tejima K, Mashima H, Tomiya T, Nagamine M, Noiri E, Omata M, Fujiwara K, Matsumoto M, Fujimura Y, Yatomi Y. Increased production of ADAMTS13 in hepatic stellate cells leads to enhanced plasma ADAMTS13 activity in rat models of cholestasis and steatohepatitis. Thromb Haemost 102: 371-378, 2009.
3. Matsuyama T, Kuwana M, Matsumoto M, Isonishi A, Inokuma S, Fujimura Y. Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases. Thromb Haemost 102: 371-378, 2009.
4. Kobayashi T, Wada H, Usui M , Sakurai H , Matsumoto T, Nobori T, Katayama N, Uemoto S, Ishizashi H, Matsumoto M, Fujimura Y, Isaji S. Decreased ADAMTS13 levels in patients with living donor liver transplantation. Thromb Res 124: 541-545, 2009.
5. Takemoto Y, Kawata H, Soeda T, Imagawa K, Somekawa S, Takeda Y, Uemura S, Matsumoto M, Fujimura Y, Jo J, Kimura Y, Tabata Y, Saito Y. Human Placental Ectonucleoside Triphosphate Diphosphohydrolase Gene Transfer via Gelatin-Coated Stents Prevents In-Stent Thrombosis.
Arterioscl Thromb Vas Biology 29: 857-862, 2009.
6. Shimizu M, Nomura S, Ishii K, Mohri Y, Umei N, Suzuki S, Matsuo Y, Isonishi A, Matsumoto M, Urase F, Maeda Y, Fujimura Y. The significence of ADAMTS13 in a patient with thrombotic thrombocytopenic purpura complicated by autoimmune hepatitis. Thromb Haemost (Letters to the Editor) 101: 599-600, 2009.
7. Fujimura Y, Matsumoto M, Kokame K, Isonishi A, Soejima K, Akiyama N, Tomiyama J, , Natori K, Kuranishi Y, Imamura Y, Inoue N, Higasa S, Seike M, Kozuka T, Hara M, H. Wada, Murata M, Ikeda Y, Miyata T, George JN. Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. Br J Hematol 144: 742-754, 2009.
8. Fujimura Y, Matsumoto M. Thrombotic thrombocytopenic purpura: Results of the patients with thrombotic microangiopathies across Japan by ADAMTS13 analysis during 1998-2008. Vox Sanguinis (Review) 4: 174-181, 2009.
9. Zakarija A, Kwaan H-C, Moake JL, Bandarenko N, Pandey DK, McKoy JM, Yarnold PR, Raisch DW, Winters JL, Raife TJ, Cursio JF, Ha Luu T-H, Richey EA, Fisher M, Ortel TL, Tallman MS, Zheng XL, Matsumoto M, Fujimura Y Bennett CL. Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic prupura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigillance findings (1989-2008). Kidney International (Review) 112: 520-524, 2009.
10. Nakagawa T, Moriki T, Yamaguchi Y, Igari A, Soejima K, Matsumoto M, Fujimura Y, Murata M. Multiple Mapping of Peptide Sequences Recognized by Various Monoclonal Anti-ADAMTS13 Antibodies with Functional or Nonfunctional Effects On the Catalytic Activity. Blood (ASH Annual Meeting Abstracts) 114: 3182, 2009
11. Matsumoto M, Isonishi A, Kato S, Ishizashi H, Yagi H, Fujimura Y.Characterization of Two Patient Groups with Acquired Idiopathic Thrombotic Thrombocytopenic Purpura, Defined by ADAMTS13 (n=195) and/or Classic Pentad (n=89). Blood (ASH Annual Meeting Abstracts) 114: 3505, 2009


2008
1. Kanno M, Nakamura S, Kawahara M, Ueno S, Nakamine H, Matsumoto M, Fujimura Y. Chemotherapy-resistent intravascular lymphoma accompanied by ADAMTS13 inhibitor successfully tretated with rituximab. Int J Hematol 88: 345-347, 2008.
2. Tripodi A, Peyvandi F, Chantarangkul V, Palla R, Afrasiabi A, Canciani MT, Chung DW, Ferrari S, Fujimura Y, Karimi M, Kokame K, Kremer-Hovinga JA, La¨mmle B, De Meyer SF, Plaimauer B, Vanhoorelbeke K, Varadi K, Mannucci PM. Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). J Thromb Haemost 6: 1534-1541, 2008.
3. Morioka C, Uemura M, Matsuyama T, Matsumoto M, Kato S, Ishikawa M, Ishizashi H, Sawai M, Yoshida M, Mitoro A, Yamao J, Tsujimoto T, Yoshiji H, Urizono Y, Hata M, Nishio K, Okuchi K, Fujimura Y, Fukui H. Plasma ADAMTS13 activity parallels the APACHE II score, reflecting an early prognostic indicator for patients with severe acute pancreatitis. Scand J Gatroenteronology 43: 1387-1396, 2008.
4. Horii M, Uemura S, Uemura M, Matsumoto M, Ishizashi H, Imagawa K, Iwama H, Takeda Y, Kawata H, Nakajima T, Fujimura Y, Saito Y. Acute myocardial infarction as a systemic prothrombotic condition evidenced by increased von Willebrand factor protein over ADAMTS13 activity in coronary and systemic circulation. Heart and Vessels 23: 301-307, 2008.
5. Furukoji E, Tanaka N, Yamashita A, Matsumoto M, Fujimura Y, Yamamoto R, Tamura S, Asada Y. Ecto-nucleoside triphosphate diphosphohydrolase inhibits ATP- and ADP-induced vasoconstriction. Thromb Res 121: 583-585, 2008.
6. Uemura M, Fujimura Y, Matsumoto M, Ishizashi H, Kato S, Matsuyama T, Isonishi A, Ishikawa M, Yagita M, Yoshiji H, Tsujimoto T, Fukui H. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 99:1019-1029, 2008.
7. Kokame M, Aoyama Y, Matsumoto M, Fujimura Y, Miyata T. Inherited and de novo mutations of ADAMTS13 in a patient with Upshaw-Schulman syndrome. J Thromb Haemost (Letters to the Editor) 6: 213-215, 2008.
8. Shida S, Nishio K, Sugimoto M, Mizuno T, Hamada M, Kato S, Matsumoto M, Okuchi K, Fujimura Y, Yoshioka A. Functional imaging of shear-dependent activity of ADAMTS13 in regulating mural thrombis growth under whole blood flow conditions. Blood 111: 1295-1298 2008.
9. Uemura M, Fujimura Y, Matsuyama T, Matsumoto M, Ishikawa M, Ishizashi H, Kato S, Tsujimoto T, Yoshiji H, Morioka C, Fukui H. Potential role of ADAMTS13 in the progression of alcoholic hepatitis. Open Gastroentenology (Review) 1: 188-196, 2008.
10. Yamaguchi Y, Moriki T, Wada H, Matsumoto M, Fujimura Y, Nakagawa T, Igari A, Ikeda Y, Murata M.Identification of ADAMTS13 Peptide Sequences Recognized by Autoantibodies in Patients with Acquired Thrombotic Thrombocytopenic Purpura.Blood (ASH Annual Meeting Abstracts) 112: 2286, 2008.
11. Ishikawa M, Uemura M, Matsuyama T, Matsumoto M, Fujimoto M, Ishizashi H, Kato S, Morioka C, Tsujimoto T, Kitazawa T, Kawaratani H, Fujimura Y, Fukui H.Potential Role of Enhanced Cytokinemia and Endotoxemia on the Decreased Activity of Plasma ADAMTS13 in Patients with Alcoholic Hepatitis. Blood (ASH Annual Meeting Abstracts) 112: 2292, 2008.
12. Morioka C, Uemura M, Matsuyama T, Matsumoto M, Fujimoto M, Kato S, Ishikawa M, Ishizashi H, Tsujimoto T, Kawaratani H, Okuchi K, Nishio K, Fujimura Y, Fukui H. Decreased Activity of Plasma ADAMTS13 Parallels Enhanced Endotoxemia in Patients with Severe Acute Pancreatitis: Relationship to Multiorgan Failure. Blood (ASH Annual Meeting Abstracts) 112: 4541, 2008.

2007
1. Matsumoto M, Kawa K, Uemura M, Kato S, Ishizashi H, Isonishi A, Yagi H, Park Y-D, Takeshima Y, Kosaka Y, Hara H, Kai S, Kanamaru A, Fukuhara S, Hino M, Sako M, Hiraoka A, Ogawa H, Hara J, Fujimura Y. Prophylactic fresh frozen plasma infusion may prevent the development of hepatic VOD after stem cell transplantation via ADAMTS13-mediated restoration of von Willebrand factor plasma levels. Bone Marrow Transplant 40: 251-259, 2007.
2. Bennett CL, Banjamin K, Zakarija A, Bandarenko N, Pandey DK, Buffie CG, McKoy JM, Tevar AD, Cursio JF, Yarnold PR, Kwaan HC, De Masi D, Sarode R, Raife TJ, Kiss JE, Raisch DW, Davidson C, Sadler JE, Ortel TL, Zheng XL, Kato S, Matsumoto M, Uemura M, Fujimura Y. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: A report from the Surveillance, Epidemiology, and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) research group and the Research on Adverse Drug Events and Reports (RADAR) project. J Am College Cardiology 50:1138-1143, 2007.
3. Yagi H, Ito S, Kato S, Hiura H, Matsumoto M, Fujimura M. Plasma levels of ADAMTS13 antigen, determined by an enzyme immunoassay using the neutralizing monoclonal antibody, parallel to those of the activity. Int J Hematology 85: 403-407, 2007.
4. Ito S, Okuyama K, Nakamura T, Tetanishi J, Saito K, Matsumoto M, Fujimura Y, Aihara Y, Yokota S. Intravenous gamma-globulin for thrombotic microangiopathy of unknown etiology. Pediatric Nephrology 22: 301-305, 2007.
5. Ishizashi H, Yagi H, Matsumoto M, Soejima K, Nakagaki T, Fujimura Y. Quantitative western blot analysis pf plasma ADAMTS13 antigen in patients with Upshaw-Schulman syndrome. Thromb Res 120: 381-386, 2007.
6. Morishita T, Matsumoto M, Honoki K, Yoshida A, Takakura Y, Fujimura Y. Successful treatment of primitive neuroectodermal tumor-associated microangiopathy with multiple bone metastasis. Jap J Clin Oncology 37: 66-69, 2007.
7. Kobayashi T, Wada H, Kamikura Y, Matsumoto T, Mori Y, Kaneko T, Nobori T, Matsumoto M, Fujimura Y, Shiku H. Decreased ADAMTS13 activity in plasma from patients with thrombotic thrombocytopenic purpura. Thromb Res 119: 447-452, 2007.
8. Fujimura Y, Matsumoto M, Yagi H. Thrombotic microangiopathy. Recent Advances in Thrombosis and Hemostasis 2008 (ed by Tanaka K, Davie EW). Springer-Verlag, pp 625-639, 2007.
9. Bennett CL, Ha Luu T, Zakarija A, Kwaan HC, Bandarenko N, Pandey DK, Cursio JF, McKoy JM, Buffie C, Winters JL, Ortel TL, Sarode R, Zheng XL, Raife TJ, Matsumoto M, Fujimura Y, Rock GA. Clinical and Outcomes Findings for Thrombotic Thrombocytopenic Purpura among 467 Persons with Severely Versus Not Severely Deficient ADAMTS-13 Levels.Blood (ASH Annual Meeting Abstracts) 110: 2088. 2007
10. Richey EA, Bennett CL, Kwaan HC, Zakarija A, Banderanko N, Pandey DK, McKoy JM, Yarnold PR, Raisch DW, Winters JL, Raife TJ, Cursio JF, Fisher MJ, Ortel TL, Tallman MS, Matsumoto M, Fujimura Y, Moake JL.Ticlopidine- and Clopidogrel-Associated Thrombotic Thrombocytopenic Purpura (TTP): Final Results from the Surveillance Epidemiology and Risk Factor-TTP Study Group.Blood (ASH Annual Meeting Abstracts) 110: 2089, 2007
11. Morioka C, Uemura M, Matsuyama T, Matsumoto M, Kato S, Ishikawa M, Ishizashi H, Fujimoto M, Tsujimoto T, Nishio K, Okuchi K, Fujimura Y, Fukui H. Plasma ADAMTS13 Activity Markedly Decreases in Patients with Severe Acute Pancreatitis: Its Potential Role on the Development of Multiorgan Failure.Blood (ASH Annual Meeting Abstracts) 110: 2160,2007
12. Fujimura Y, Matsumoto M, Kokame K, Yagi H, Isonishi A, Matsuyama T, Kato S, Ishizashi H, Shida Y, Kenji N, Akiyama N, Tomiyama J, Natori K, Kuraishi Y, Imamura Y, Inoue N, Higasa S, Seike M, Kozuka T, Hara M, Sugimoto M, Wada H, Murata M, Miyata T, Ikeda Y. Natural History of 33 Patients with Upshaw-Schulman Syndrome Has Revealed That All the Gravida Develop Thrombocytopenia, Often Followed by Thrombotic Microangiopathy with Stillbirth. Blood (ASH Annual Meeting Abstracts) 110: 3211, 2007.
13. Matsuyama T, Matsumoto M, Isonishi A, Inokuma S, Fujimura Y. Analysis of ADAMTS13 and Its IgG-Autoantibodies in 170 Patients with Connective Tissue Disease-Associated Thrombotic Microangiopathy Indicates More Than 2 Types on Its Pathogenesis.Blood (ASH Annual Meeting Abstracts) 110: 1322, 2007.


2006
1. Matsuyama T, Uemura M, Ishikawa M, Matsumoto M, Ishizashi H, Kato S, Morioka C, Fujimoto M, Kojima H, Yoshiji H, Takimura C, Fujimura Y, Fukui H. Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. Alcohol Clin Exp Res 31: 27S-35S, 2006.
2. Kitano K, Gibo Y, Kamijo A, Furuta K, Oguchi S, Joshita S, Takahashi Y, Ishida F, Matsumoto M, Uemura M, Fujimura Y. Thrombotic thrombocytopenic purpura associated with pegylated-interferon alpha-2a by an ADAMTS13 inhibitor in a patient with chronic hepatitis C. Hematologica (on line) 91(1) 5-7, 2006.
3. Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel monoclonal antibody-based immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion 46: 1444-1452, 2006.
4. Sato T, Hanaoka R, Ohshima M, Miwa Y, Okazaki Y, Uajima N, Ishizashi H, Matsumoto M, Fujimura M, Inokuma S. Analysis of ADAMTS13 activity and its inhibitor in patients with thrombotic thrombocytopenic purpura secondary to connective tissue diseases: Observations in a single hospital. Clin Exp Rheumatol (Letters to the Editor) 24:454-455, 2006.
5. Ko S, Okano H, Kanehiro H, Matsumoto M, Ishizashi H, Uemura M, Fujimura Y, Tanaka K, Nakajima Y. Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: Observations in 3 cases. Liver Transplantation 12:859-869, 2006.
6. Shibagaki Y, Matsumoto M, Kokame K, Ohba S, Miyata T, Fujimura Y, Fujita T. Novel compound heterozygote mutations (H234Q/R1206X) of the ADAMTS13 gene in an adult patient with Upshaw-Schulman syndrome showing predominant episodes of repeated acute renal failure. Nephrol Dial Transplant 21: 1289-1292, 2006.
7. Uemura M, Kato S, Matsumoto M, Ishizashi H, Isonishi A, Hiura H, Matsuyama T, Yagi H, Ishikawa M, Fujimoto M, Kojima H, Yoshiji H, Fujimura Y, Fukui H.Increased Plasma VWF Antigen over Decreased ADAMTS13 Activity in Patients with Liver Cirrhosis: Relationship to Degree of Liver Disturbance and Clinical Features. Blood (ASH Annual Meeting Abstracts) 108: 1496, 2006.
8. Matsumoto M, Kawa K, Yagi H, Park YD, Takeshima Y, Kosaka Y, Hara H, Kai S, Yamamoto M, Kanemaru A, Fukuhara S, Hino M, Sako M, Hiraoka A, Ogawa H, Hara J, Fujimura Y.Infusions of Fresh Frozen Plasma to the Patients with a High-Risk Group for Hepatic VOD Associated with Stem Cell Transplantation Reduce Its Occurrence. Blood (ASH Annual Meeting Abstracts), 108: 1502, 2006.

2005
1. Uemura M, Matsuyama T, Fujimoto M, Kojima H, Sakurai S, Ishii S, Toyohara M, Yamazaki M, Yoshiji H, Yamao J, Matsumoto M, Ishizashi H, Fujimura Y, Fukui H. Decreased activity of plasma ADAMTS13 may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. Alcohol Clin Exp Res 29: 264-71, 2005.
2. Matsumoto M, Kawaguchi S, Ishizashi H, Yagi H, Iida J, Sakaki T, Fujimura Y. Platelets treated with ticlopidine are less reactive to unusually large VWF multimers than are those treated with aspirin under high shear stress. Pathophy Haemost Thromb 34: 35-40, 2005.
3. Uemura M, Tatsumi K, Matsumoto M, Fujimoto M, Matsuyama T, Ishikawa M, Iwamoto T, Mori T, Wanaka A, Fukui H, Fujimura Y. Localization of ADAMTS13 to the stellate cells of human liver. Blood 106: 922-924, 2005.
4. Kosugi S, Matsumoto M, Ohtani Y, Take H, Ishizashi H, Fujimura Y, Kuyama J. Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura. Int J Hematol 81: 433-436, 2005.
5. Fujisaki K, Matsutani K, Yoshimitsu T, Nakanishi K, Matsumoto M, Yagi H, Ishizashi H, Fujimura Y, Takeda K, Hirakata H, Iida M. Thrombotic thrombocytopenic purpura associated with polyarthritis nodosa: demonstration of the inhibitor against von Willebrand factor-cleaving protease. Clinical Nephrology 64: 305-310, 2005.
6. Sugimoto T, Saigo K, Shin T, Kaneda Y, Manabe N, Narita H, Wakuya J, Imoto S, Murayama T, Matsumoto M, Fujimura Y, Nishimura R, Koizumi T, Kumagai S. Von Willebrand factor-cleaving protease activity remains at the intermediate level in thrombotic thrombocytopenic puroura. A chronic myelogenous case treated with interferon-a. Acta Hematologica 113:198-203, 2005.
7. Hatakeyama K, Hao H, Imamura T, Ishikawa T, Shibata Y, Fujimura Y, Eto T, Ogawa H, Asada Y. Decreased CD39 expression in coronary artherosclerotic lesions is implicated in plaque instability and thrombus formation. Am J Cardiol 95: 632-635, 2005.
8. Furukoji E. Matsumoto M, Yamashita A, Yagi H, Sakurai Y, Marutsuka K, Hatakeyama K, Morishita K, Fujimura Y, Tamura S, Asada Y. Adenovirus-mediated transfer of human placental ecto-ATP diphosphohydrolase I to vascular smooth muscle cells suppresses platelet aggregation in vitro and arterial thrombus formation in vivo. Circulation 111: 808-815, 2005.
9. Yagita M, Uemura M, Nakamura T, Kunitomi A, Matsumoto M, Fujimura Y. Development of ADAMTS13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenic puroura. J Hepatology (Letters to the Editor) 42: 420-421, 2005.
10. Fujimura Y. Down-regulation of ADAMTS13 activity by serine proteases. Blood (Inside Blood) 105: 911-912, 2005.
11. Kato S, Matsumoto M, Matsuyama T, Hiura H, Fujimura Y.Monoclonal Antibodies to a VWF-A2 Decapeptide with the C-Terminal Residue Tyr1605, Generated by ADAMTS13 Cleavage, Develop a Highly Sensitive ELISA for Its Activity and Characterize Upshaw-Schulman Syndrome.Blood (ASH Annual Meeting Abstracts), 106: 2643, 2005
12. Matsuyama T, Matsumoto M, Kato S, Akiyama N, Tomiyama J, Natori K, Kuraishi Y, Imamura Y, Inoue N, Kokame K, Miyata T, Fujimura Y.Upshaw-Schulman Syndrome: A Masqueraded Thrombocytopenia during Pregnancy. Blood (ASH Annual Meeting Abstracts) 106: 2644, 2005.


2004
1. Kawahara M, Kanno M, Matsumoto M, Nanno H, Danno D, Murata K, Nakamura S, Fujimura Y, Ueno S. Diffuse neurodeficits in intravascular lymphomatosis with ADAMTS13 inhibitor. Neurology 63: 1731-1733, 2004.
2. Uchida T, Wada H, Mizutani M, Iwashita M, Ishihara H, Shibano T, Suzuki M, Matsubara Y, Soejima K, Matsumoto M, Fujimura Y, Ikeda Y, Murata M. Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura. Blood 104: 2081-2083, 2004.
3. Matsumoto M, Kokame K, Soejima K, Miura M, Hayashi S, Fujii Y, Iwai A, Ito E, Tsuji Y, Takada-Shitaka M, Iwadate M, Umeyama H, Yagi H, Ishizashi H, Banno F, Nakagaki T, Miyata T, Fujimura Y. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood 103: 1305-1310, 2004.
4. Matsumoto M, Yagi H, Ishizashi H, Wada H, Fujimura Y. The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Seminar in Hematol 41: 68-74, 2004.
5. Kokame K, Matsumoto M, Fujimura Y, Miyata T. VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood 103: 607-612, 2004.


2003
1. Fujimura Y. Is Upshaw-Schulman syndrome congenital TTP or HUS? Yes on the both. J Thromb Haemost (Letters to the Editor) 1: 2457-2458, 2003.
2. Soejima K, Matsumoto M, Kokame K, Yagi H, Ishizashi H, Maeda H, Nozaki C, Miyata T, Fujimura Y, Nakagaki T. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood 102: 3232-3237, 2003.
3. Nakazawa Y, Hashikura Y, Ogino S, Urata K, Ikegami T, Terada M, Yagi H, Ishizashi H, Matsumoto M, Fujimura Y, Kawasaki S. Significance of measuring von Willebrand factor-cleaving protease activity in thrombotic microangiopathy after living donor liver transplantation. Liver Transplant 9: 1328-1333, 2003.
4. Sakurai Y, Shima M, Matsumoto M, Takatsuka H, Nishiya K, Kasuda S, Fujimura Y, Yoshioka A. Anticoagulant activity of M-LAO, L-amino acid oxidase purified from Agkistrodon halys blomhoffi, through selective inhibition of factor IX. Biochem Biophys Acta 1649: 51-57, 2003.
5. Wang J, Kimura T, Asada R, Harada S, Yokota S, Kawamoto Y, Fujimura Y, Tsuji T, Ikehara S, Sonoda Y. SCID-repopulating cell activity of human cord blood-derived CD34-negative cells assured by intra-bone injection. Blood 101:2924-2931, 2003.
6. Fujimura Y. TTP: VWF and ADAMTS-13. Int J Hematol (Review). pp77-83, 2003.
13. Matsumoto M, Yagi H, Ishizashi H, Wada H, Fujimura Y. The Japanese experience of TTP/ HUS: Analysis of 290 patients. Blood (ASH Annual Meeting Abstracts) 102: 2973, 2003.
14. Murata M, Uchida T, Suzuki M, Matsubara Y, Tanahashi N, Ogawa S, Saito I, Watanabe K, Matsumoto M, Fujimura Y, Ikeda Y. Screening of single nucleotide polymorphisms in the ADAMTS 13 (von Willebrand factor-cleaving protease) gene and studies on their association with stroke and coronary artery disease. Blood (ASH Annual Meeting Abstracts) 102: 2968, 2003


2002
1. Sugimoto M, Matsui H, Mizuno T, Tsuji S, Miyata S, Matsumoto M, Matsuda M, Fujimura Y, Yoshioka A. Mural thrombus generation in type 2A and 2B von Willebrabd disease under high shear conditions. Blood 101: 915-920, 2002.
2. Yasuzawa-Amano S, Inoue M, Yoshida Y, Yagi H, Ishizashi H, Matsumoto M, Fujimura Y, Yoshioka A. Intensive plasma IgG removal therapy for severe thrombotic thrombocytopenic purpura. Int J Hematol 76: 474-476, 2002.
3. Ashida A, Nakamura H, Yoden A, Tamai H, Ishizashi H, Yagi H, Matsumoto M, Fujimura Y. Successful treatment of a young infant who developed high-titer inhibitors against VWF-cleaving protease (ADAMTS-13): Important discrimination from Upshaw-Schulman syndrome. Am J Hematol 71: 318-322, 2002.
4. Kokame K, Matsumoto M, Soejima K, Yagi H, Ishizashi H, Funato M, Tamai H, Konno M, Kamide K, Kawano Y, Miyata T, Fujimura Y. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 99: 11902-11907, 2002.
5. Matsuda J, Sanaka T, Gohchi K, Matsui K, Uchida S, Matsumoto M, Fujimura Y. Occurrence of thrombotic thrombocytopenic purpura in a systemic lupus erythrematosus patient with antiphospholipid antibodies in association with a decreased activity of von Willebrand factor-cleaving protease. Lupus 11: 463-464, 2002.
6. Matsui T, Hamako J, Matsushita T, Nakayama T, Fujimura Y, Titani K. Binding site on human von Willebrand factor of bitiscetin, a snake venom-derived platelet aggregation inducer. Biochemistry USA 41: 7939-7946, 2002.
7. Park Y-D, Yoshioka A, Kawa K, Ishizashi H, Yagi H, Yamamoto Y, Matsumoto M, Fujimura Y. Impaired activity of plasma von Willebrand factor-cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation. Bone Marrow Transplant 29: 789-794, 2002.
8. Mori Y, Wada H, Gabazza EC, Minami N, Nobori T, Shiku H, Yagi H, Ishizashi H, Matsumoto M, Fujimura Y. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion 42: 572-580, 2002.
9. Hayashi T, Yagi H, Suzuki H, Nonaka Y, Nomura T, Sakurai Y, Shibata M, Matsumoto M, Yamamoto Y, Fujimura Y. Low-dosage intravenous immunoglobulin in the management of a patient with acquired von Willebrand syndrome associated with monoclonal gammopathy of undetermined significance. Pathophys Haemost Thromb 32: 33-39, 2002.
10. Orimo S, Ozawa E, Yagi H, Ishizashi H, Matsumoto M, Fujimura Y. Simple plasma exchange reduced autoantibody to von Willebrand factor-cleaving protease in a Japanese man with ticlopidine-associated thrombotic thrombocytopenic purpura. J Intern Med 251: 280-281, 2002.
11. Fujimura Y, Matsumoto M, Yoshioka A, Matsui T, Titani K. von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome. In: Progress in Hematology. Int J Hematol (Review) 75: 25-34, 2002.
15. Yagi H, Matsumoto M, Ishizashi H, Soejima K, Nakagaki T, Kokame K, Miyata T, Kimura H, Fujimura Y. Recombinant ADAMTS13 rapidly and preferentially cleaves unusually- large von Willebrand factor multimers in the plasmas with Upshaw-Schulman syndrome under high shear stress. Blood (ASH Annual Meeting Abstracts) 100: 2699, 2002 12.


2001
1. Yagi H, Konno M, Kinoshita S, Matsumoto M, Ishizashi H, Matsui T, Titani K, Fujimura Y. Plasma of patients with Upshaw-Schulman syndrome, a congenital deficiency of von Willebrand factor-cleaving protease activity, enhances the aggregation of normal platelets under high shear stress. Br J Hematol 115: 991-997, 2001.
2. Sakurai Y, Takatsuka H, Yoshioka A, Matsui T, Suzuki M, Titani K, Fujimura Y. Inhibition of human platelet aggregation by L-amino acid oxidase purified from Naja kaouthia venom. Toxicon 39: 1827-1833, 2001.
3. Sugio Y, Okamura T, Shimoda K, Matsumoto M, Yagi H, Ishizashi H, Niho Y, Inaba S, Fujimura Y. Ticlopidine-associated thrombotic thrombocytopenic purpura with an IgG-type inhibitor to von Willebrand factor-cleaving protease activity. Int J Hematol 74: 347-351, 2001.
4. Kinoshita S, Yoshioka A, Park Y-D, Ishizashi H, Konno M, Funado M, Matsui T, Titani K, Yagi H, Matsumoto M, Fujimura Y. Upshaw-Schulman syndrome revisited: A concept of congenital thrombotic thrombocytopenic purpura. Int J Hematol 74: 101-108, 2001.
5. Ito M, Hamako J, Sakurai Y, Matsumoto M, Fujimura Y, Suzuki M, Hashimoto K, Titani K. Complete amino acid sequence of kaouthiagin, a novel cobra venom metalloproteinase with two disintegrin-like sequences. Biochemistry USA 40:4503-4511, 2001.
6. Yagi H, Narita N, Matsumoto M, Sakurai Y, Ikari H, Yoshioka A, Kita E, Ikeda Y, Titani K, Fujimura Y. Enhanced low shear stress-induced platelet aggregation by Shiga-like toxin 1 purified from Escherichia coli O157. Am J Hematol 66: 105-115, 2001
7. Takatsuka H、Sakurai Y、Yoshioka A、Kokubo T、Usami Y 、Suzuki M、Titani K、Yagi H、Matsumoto M、Fujimura Y. Molecular characterization of L-amino acid oxidase from Agkistrodon halys blomhoffi with special reference to platelet aggregation. Biochem Biophys Acta 1544: 267-277, 2001.
16. Yagi H, Matsumoto M, Kimura H, Ishizashi H, Matsui, T, Titani K, Fujimura Y.Purified vWF-cleaving prtease normalizes the hightened high shear stress induced platelet aggregation using plasmas with Upshaw- Schulman syndrome. Blood (ASH Annual Meeting Abstracts) 98: 3139, 2001

2000
1. Satoh K, Asazuma N, Yatomi H, Fujimura Y, Miura S, Titani K, Ozaki Y. Activation of protein-tyrosine kinase pathways in human platelets stimulated with the A1 domain of von Willebrand factor. Platelets 11: 171-176, 2000.
2. Nomura S, Imamura A, Okuno S, Komiyama N, Fujimura Y, Ikeda Y, Fukuhara S. Platelet-derived microparticles in patients with arteriosclerosis obliterans: Enhancement of high shear-induced microparticle generation by cytokines. Thromb Res 98: 257-268, 2000.
3. Taniuchi Y, Kawasaki T, Fujimura Y. The high molecular mass, glycoprotein Ib-binding protein Flavocetin-A induces only small platelet aggregation in vivo. Thromb Res 97: 69-75, 2000.
4. Yamamoto T, Moriwaki Y, Fujimura Y, Takahashi S, Tsutsumi Z, Tsutsui T, Higashino K, Hada T. Effect of TEI-6720, a xanthine oxidase inhibitor, on the nucleoside transport in the lung cancer cell line A549. Pharmacology 60: 34-40, 2000.
5. Matsui T, Fujimura Y, Titani K. Snake venom proteases affecting hemostasis and thrombosis. Biochim Biphys Acta (Review) 1477: 146-156, 2000.
6. Matsumoto M, Chisuwa H, Nakazawa Y, Ikegami, T, Hashikura Y, Kawasaki S, Yagi H, Ishizashi H, Matsui T, Titani K, Fujimura Y. Liver transplantation rescues a deficient state of von Willebrand factor-cleaving protease activity in patients with liver cirrhosis due to congenital biliary atresia. Blood (ASH Annual Meeting Abstracts) 96: 2733, 2000
7. Park YD, Yoshioka A, Kawa K, Ishizashi H, Yagi H, Matsumoto M, Fujimura Y. Impaired activity of plasma von Willebrand factor-cleaving protease in patients with hepatic veno-occulsive disease after bone marrow transplantation. Blood (ASH Annual Meeting Abstracts) 96:1669, 2000
8. Yagi H, Matsumoto M, Ishizashi H, Kinoshita S, Konno M, Matsui T, Titani K, Fujimura Y. Plasmas with Upshaw-Schulman syndrome, a congenital deficiency of von Willebrand factor-cleaving protease, augment the aggregation of normal washed platelets under high-shear -stress. Blood (ASH Annual Meeting Abstracts) 96:2707, 2000

>ページTOPへ

業績/和文


2009
1. 藤村吉博. 血栓性血小板減少性紫斑病の診断と治療. 日本医事新報 4435: 45-51, 2009.
2. 松本雅則、藤村吉博.ADAMTS13とTTP−最近の進歩−.Annual Review血液2009.pp209-216.2009
3. 植村正人、藤村吉博、福井博.「消化器病学の進歩―原点から未来への情報発信」III.複合領域.ワークショップ3.多臓器病変を呈する消化器疾患.重症肝・膵疾患における多臓器不全の病態解析―ADAMTS13を中心に.第94回日本消化器病学会総会記念誌 pp262-266, 2009.
4. 松本雅則、藤村吉博.出血性疾患:診断と治療の進歩.II.検査法の進歩−3.von Willebrand因子切断酵素(ADAMTS13).日本内科学会雑誌 98:36-42, 2009.
5. 藤村吉博、松本雅則、植村正人、杉本充彦、小亀浩市、宮田敏行.第45回2008年度ベルツ賞受賞論文ー2等賞:動脈血栓症の制圧ーVWF-GPIb軸依存性血小板血栓形成を調節するADAMTS13の基礎臨床病態解析ー最新医学社 64:132-163. 2009.
6. 藤村吉博. 血栓性血小板減少性紫斑病の病態と治療. 血液・腫瘍科 58:623-630, 2009.
7. 藤村吉博. 新しい診断と治療のABC.血小板減少症・増加症. 第4章.血栓性血小板減少性紫斑病:病態・病型分類. 最新医学社(池田康夫 編集) pp121-132. 2009.
8. 藤村吉博.石西綾美、松本雅則. ADAMTS13の最近の話題. Coagulation & Inflammation 3: 1-9, 2009

2008
1. 藤村吉博.へパリン起因性血小板減少症(HIT)の診断と治療. 日本産婦人科会報 1月号:8-9, 2008.
2. 植村正人、藤村吉博.血液浄化法の臨床:単純血漿交換・二重膜濾過血漿交換・血漿吸着―血液疾患.88.TTP.腎と透析 65:421-427, 2008.
3. 植村正人、藤村吉博.腎不全と血栓:急性腎不全−2)血栓性血小板減少性紫斑病.血液と循環 16:15-21, 2008.
4. 藤村吉博、植村正人. 肝産生酵素ADAMTS13と血栓症. 臨床血液  49:136-149, 2008.
5. 藤村吉博. 腎不全と血栓:急性腎不全−2)血栓性血小板減少性紫斑病.血液と循環 16:15-21, 2008.
6. 藤村吉博. 第105回日本内科学会講演会―教育講演−9.血栓性血小板減少性紫斑病の病態と治療.  日本内科学会雑誌 97:295-302, 2008.
7. 藤村吉博. 血栓止血の臨床―研修医のためにIV.TTPの診断と治療.  日本血栓止血学会雑誌 19:358-362, 2008.
8. 松本雅則、藤村吉博.「von Willebrand病―最近の進歩」 Annual Review 血液2008. 中外医学社 2008



2007
1. 金子仁臣, 松本雅則, 岡本浩平, 蝶名林和久, 菱沢方勝, 渡邊光正, 藤村吉博, 通堂満、Rituximabとvincristine併用が奏効した難治性血栓性血小板減少性紫斑病. 臨床血液48:144-147,2007 
2. 藤村吉博. 「血栓性血小板減少性紫斑病 TTP」今日の治療指針. 医学書院2006
3. 八木秀男、藤村吉博. 「血栓性血小板減少性紫斑病(TTP)」 専門医のための薬物療法Q&A 血液. 中外医学社 2007
4. 藤村吉博. 「藩種性血管内凝固症 DIC」 内科学. 朝倉書店 2007
5. 藤村吉博. 「血栓性血小板減少性紫斑病 TTP」 内科学. 朝倉書店 2007
6. 藤村吉博.血栓性微小血管障害症. 臨床血液  47:734-746, 2007.
7. 八木秀男、松本雅則、藤村吉博.血栓症. Modern Physician 27: 518-521, 2007.
8. 加藤誠司、藤村吉博.新しい血栓症のマーカーADAMTS13.Medical Technology 35:120-121, 2007.
9. 八木秀男、松本雅則、藤村吉博.血栓性微小血管障害症による脳神経症状.日本内科学会雑誌 96:157-165, 2007.


2006
1. 松山友美、植村正人、石川昌利、森岡千恵、藤本正男、櫻井伸也、小嶌秀之、吉治仁志、福井博、松本雅則、石指宏通、加藤誠司、藤村吉博、瀧村力、アルコール性肝炎における血漿ADAMTS13活性低下の機序―サイトカインならびにインヒビターの面からの検討―. アルコールと医学生物学. 26:100-107、2006
2. 洪鉉寿、青山泰孝、山村亮介、太田忠信、麥谷安津子、山根孝久、日野雅之、松本雅則、藤村吉博. Rituximab投与が奏効し、長期寛解を維持している血漿交換抵抗性重症血栓性血小板減少性紫斑病. 臨床血液47:1528-1532, 2006
3. 藤村吉博. 「血小板減少症」小児輸血学. 中外医学社 2006
4. 杉本充彦、藤村吉博. 「von Willebrand病」 三輪血液病学.  文光堂 2006
5. 松本雅則、藤村吉博. 「血栓性疾患 血栓性血小板減少性紫斑病(TTP)」三輪血液病学. 文光堂 2006
6. 八木秀男、藤村吉博. 「血栓性疾患 溶血性尿毒症症候群(HUS)」三輪血液病学. 文光堂 2006
7. 八木秀男、藤村吉博. 「血栓性血小板減少性紫斑病」血栓症ナビゲーター. メディカルレビュー社 2006
8. 藤村吉博.血栓性血小板減少性紫斑病の分子病態.マクロファージフォーラム 13:511-517, 2006.
9. 藤村吉博.Upshaw-Schulman症候群―仮面血小板減少症. 日本小児科学会雑誌 110:1491-1504, 2006.
10. 藤村吉博,石西綾美.血栓性血小板減少性紫斑病.成人病と生活習慣病 36:206-210, 2006.
11. 藤村吉博.TMAの診断と血小板輸血の重要指標. 日本血栓止血学会誌 17:144-164, 2006.

2005
1. 黒田裕行、木田雅也、渡辺秀樹、松永卓也、新津洋司郎、松本雅則. Evans症候群を合併したBasedow. 臨床血液 46:1118-1122、2005.
2. 大渡五月、松本雅則、高塚祥芝、竹内章吾、牧野虎彦、魚住公治、藤村吉博、宇都宮興. 胃癌の骨髄転位に併発した血栓性血小板減少性紫斑病. 臨床と研究 82:1379-1382, 2005
3. 山根隆志、田中千尋、村田美紀、柱本照、三浦靖史、塩沢俊一、宮本宣友、前川修司、金澤健司、橋本正良、秋田穂束、松本雅則、石指宏通、藤村吉博. 血漿交換が著効したSLEに合併したTTPの1例. 臨床リウマチ17:48-52, 2005
4. 松山友美、植村正人、石川昌利、藤本正男、小嶌秀之、櫻井伸也、石井禎庸、浪崎正、豊原眞久、山崎正晴、吉治仁志、山尾純一、福井博、松本雅則、石指宏通、加藤誠司、藤村吉博、瀧村力.アルコール性肝炎におけるADAMTS13と von Willebrand因子の動態―重症度との関連―. アルコールと医学生物学. 25:112-117、2005
5. 藤村吉博.  「TTP/HUS」 血栓・止血・血管 血栓症制圧のために.  中外医学社 2005
6. 松本雅則、藤村吉博. 「遅発型輸血副作用」 周術期の輸液・輸血療法. 文光堂 2005
7. 植村正人、藤村吉博.血栓症に関するQ&A―薬剤によるTTPの発症機序とその場合の治療について教えて下さい.血栓と循環 13:204-208, 2005.
8. 藤村吉博.TTP~ADAMTS13の動態解析. Hematological Malignancy Review No.30, 2005.

2004
1. 森美貴、和田英夫、珠玖洋、八木秀男、松本雅則、藤村吉博. TMA症例におけるADAMTS13活性と血管内皮細胞マーカーの検討。臨床血液 45: 2004
2. 植村正人、石川昌利、松山友美、田村信宏、藤本正男、今津博雄、小嶌秀之、櫻井伸也、石井禎暢、浪崎正、豊原眞久、山崎正晴、吉治仁志、山尾純一、福井博、松本雅則、八木秀男、藤村吉博、石指宏通. アルコール性肝炎におけるvon Willebrand因子(vWF)特異的切断酵素(ADAMTS13)の動態. アルコールと医学生物学 24. 132-136. 2004
3. 畑間繁樹、田中理恵子、土井俊樹、小池清美、中山勝、武田一人、松本雅則、八木秀男、石指宏通. 血液浄化療法が有効であった混合型クリオグロブリン血漿合併の溶血性尿毒症症候群/血栓性血小板減少性紫斑病の1例. 透析会誌 37:79-84,2004
4. 松本雅則、藤村吉博. 「血栓性血小板減少性紫斑病(TTP)」血液疾患ハンドブック. 医薬ジャーナル社 2004
5. 藤村吉博. 「血栓性血小板減少性紫斑病、溶血性尿毒性症候群」 今日の治療と看護[改訂第2版] 南江堂 2004
6. 松本雅則、藤村吉博. 「血小板活性化抑制経路」血小板生物学. メディカルレビュー社 2004
7. 八木秀男、藤村吉博. 「von Willebrand因子」血小板生物学. メディカルレビュー社 2004
8. 藤村吉博. VWF切断酵素(ADAMTS13)の動態解析によるTTP/HUS診断法の進歩.日本内学会雑誌 93:9-17, 2004.
9. 藤村吉博.TTP/HUS患者への血漿交換療法の適応と血小板輸血の禁忌. 奈良県医師会透析部会誌 9:13-22,2004.
10. 八木秀男、藤村吉博.TTPの発症機序と病態. 血液・腫瘍科 49:128-134, 2004.
11. 加藤誠司、藤村吉博.VWF切断酵素(von Willebrand factor-cleaving protease: VWF-CP). 血栓と循環 12:188-192, 2004.
12. 八木秀男、藤村吉博.今月の主題―新しい自己抗体:TTP/HUSのADAMTS13インヒビター.臨床検査 48: 289-295, 2004.

 


2003
1. 藤村吉博. 「TTPとADAMTS13変異」 Annual Review 血液. 中外医学社 2003
2. 藤村吉博.von Willebrand factor-cleaving proteaseについて.Die Nische 11:5-8, 2003.
3. 藤村吉博. 第45回日本臨床血液学会総会 教育講演10:TTP/HUSとVWF/ADAMTS13. 臨床血液 44:1144-1153, 2003.
4. 藤村吉博. 特集:血液疾患研究の進歩〜歴史的検証〜 血栓性血小板減少性紫斑病. 血液フロンテイア13: 71-83,2003.
5. 藤村吉博. von Willebrand factor-cleaving protease. 臨床検査 47:881-886, 2003.
6. 藤村吉博.細血管障害性溶血性貧血-種類・分類―. 血液フロンテイア13: 9-16,2003.
7. 藤村吉博.TTPとHUS. 医学のあゆみ 206:101-104,2003.

2002
1. 高川健,中島充,平康二,坂上義次,上田卓,赤澤英樹,丸橋欣之,下山弘展,高橋幸博,藤村吉博,上辻秀和,吉岡章.小児微小変化型ネフローゼ症候群におけるずり応力惹起血小板凝集. 日腎会誌44:380-388,2002.
2. 山崎哲,瀧正志,安室洋子,高山成伸,三宅良彦,藤村吉博,鈴木康夫.膠原病におけるvon Willebrand因子特異的切断酵素と抗リン脂質との関連. 臨床病理50:301-307,2002
3. 藤村吉博.今日の治療指針ー血栓性血小板減少性紫斑病.医学書院2002
4. 八木秀男、藤村吉博.  「何が原因?この血小板減少」血液疾患を探る. 永井書店 2002
5. 藤村吉博. 「病態をちゃんと理解しましょう」「紫斑と関節痛、いつか覚えた記憶はあるけれど」血液疾患を探る. 永井書店 2002
6. 松本雅則、藤村吉博. 「なぜ、血小板がこわれるの?」 血液疾患を探る. 永井書店 2002
7. 藤村吉博. 「意識障害と出血性傾向を認めた41歳男性」 血液疾患[第3版] 日本医事新報社 2002
8. 藤村吉博. 脳梗塞の再発をどうふせぐか:危険因子からの検討―1.血栓形成のメカニズムと危険因子. 第16回チクロピジンシンポジウムハイライト 2002.
9. 藤村吉博. 血栓症を理解するための基礎知識:vWF-cleaving protease. 臨床医 28:2262-2264, 2002.
10. 八木秀男、松本雅則、藤村吉博. 血栓性血小板減少性紫斑病. 日本検査血液学会雑誌 3:367-374,2002
11. 藤村吉博. Review: TTPとADAMTS13. Currents in Hematoimmunology 18: 4-9, 2002.
12. 藤村吉博. 病的血栓の発生機序:VWFに依存した血小板凝集に関する最近知見. 第66回日本循環器学会ファイアサイドセミナー Medical Tribune 6月27日号、2002.

2001
1. 藤村吉博.「止血異常症」小児輸血療法.南江堂2001
2. 藤村吉博. 「TTPとHUS」,「新鮮凍結血漿」,「濃厚血小板」,新しいDICの病態・診断・治療. 医薬ジャーナル社 2001
3. 藤村吉博. von Willebrand病.血液学ケーススタディ124例.医薬ジャーナル2001
4. 藤村吉博. 第42回日本臨床血液学会総会 教育講演9:Upshaw-Schulman症候群の病態と治療. 臨床血液 42:76-80, 2001.
5. 藤村吉博.HUS/TTPとVWFプロテアーゼ. 日本輸血学会雑誌47:445-447,2001


2000
1. 三間屋純一,立浪忍,瀧正志,山元泰之,花房秀次,藤村吉博,照沼裕,加藤真吾,吉田孝人. 本邦におけるHIV感染長期未発症者の実態. 日本エイズ学会誌 2:89-95,2000.
2. 岡本康幸,大西雅人,山中貴世,藤村吉博,嶋緑倫,吉岡章,建島澄子,久保田力,中野博.血友病A患者におけるGBV-C/HGVウイルスの検出とそのgenotypeの検討.臨床病理47:571-575,2000.
3. 吉田剛祥,藤村吉博,河本順雄,朴永東,下山丈人,斉藤滋,森川肇.奈良臍帯血サブバンクにおける臍帯血造血幹細胞の調整と機能保持に燗する研究.産婦の進歩52:437-447,2000.

>ページTOPへ